Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model

Samankaltaisia teoksia

• IL-12 stimuli during ex vivo expansion not only prevents the upregulation of PD1 on tumor infiltrating adoptively transferred T cells but also on endogenous TILs which results in effective tumor regression
  Tekijä: Diaz-Montero, C Marcela, et al.
  Julkaistu: (2014)
• Accumulation of MDSC subsets in renal cell carcinoma correlates with grade and progression free survival, and is associated with intratumoral expression of IL-1β, IL-8 and CXCL5
  Tekijä: Najjar, Yana G, et al.
  Julkaistu: (2014)
• MDSC as a Mechanism of Tumor Escape from Sunitinib Mediated Anti-Angiogenic Therapy
  Tekijä: Finke, James, et al.
  Julkaistu: (2011)
• Preclinical to clinical translation of anti-PD-1 blockade
  Tekijä: Hirsch, Heather, et al.
  Julkaistu: (2015)
• Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
  Tekijä: Spahn, Jessica, et al.
  Julkaistu: (2015)